A study supported the idea that combining cordycepin with CTLA-4 blockade could modify the effector and exhaustion status of CD8+ T cell, thereby bolstering CD8+ T cell-mediated anti-tumor immunity in the TME. This evidence concerns the gene CD8A and neoplasm.